FOXO4-DRI

FOXO4-DRI (FOXO4-D Retro-Inverso) is described as a modified protein version of FOXO4 that uses D-amino acids to help it stay in the body longer. It’s discussed for targeting senescent (non-functional) cells by binding to p53, supporting p53-mediated removal of dysfunctional cells. (Research/educational context only.)

Deeper Research Notes (Summary):
• Described as promoting apoptosis (cell death) specifically in non-functional/senescent cells, supporting improved tissue health and function.
• Described as interacting with FOXO proteins involved in insulin response; by influencing insulin signaling it may help lower fasting blood sugar, potentially reducing diabetes-related complication risk.
• Described as boosting proteasome function (cellular cleanup), helping remove damaged proteins and reduce oxidative stress in heart and brain tissues—supporting cardiovascular and neurological function.

Dosing & Cycling (As Listed):Note: The source states there is limited information available on FOXO4-DRI dosing and cycling.

Caution & Contraindications:
Caution:
• May cause headache, fatigue, and stomach discomfort
• Use caution in individuals with a history of current blood sugar complications
Contraindications:
• Unknown at the moment due to limited research

Reconstitution Options (Vial Format):
• 10 mg

Reconstitution (General Handling):
• Use sterile technique and sanitize the vial stopper before access.
• Add diluent slowly along the vial wall to minimize foaming.
• Gently swirl/roll until fully dissolved (avoid vigorous shaking).
• Store according to the product label/spec sheet and protect from light as applicable.

Sequence: H-D-Leu-D-Thr-D-Leu-D-Arg-D-Lys-D-Glu-D-Pro-D-Ala-D-Ser-D-Glu-D-Ile-D-Ala-D-Gln-D-Ser-D-Ile-D-Leu-D-Glu-D-Ala-D-Tyr-D-Ser-D-Gln-D-Asn-D-Gly-D-Trp-D-Ala-D-Asn-D-Arg-D-Arg-D-Ser-D-Gly-D-Gly-D-Lys-D-Arg-D-Pro-D-Pro-D-Pro-D-Arg-D-Arg-D-Arg-D-Gln-D-Arg-D-Arg-D-Lys-D-Lys-D-Arg-D-Gly-OH

Molecular Formula: C228H388N86O64

Molecular Weight: 5358.05 g/mol

Synonyms: Forkhead box protein O4 (FOXO4), Proxofim, FOXO4a, AFX, MLLT7

Retro-inverso peptides reverse sequence order and replace L-amino acids with D-isomers. Side-chain orientation is preserved for receptor recognition, yet proteolytic enzymes cannot easily degrade the peptide—extending serum half-life and improving cell penetration.

FOXO4-DRI restores p53 activity in senescent cells, inducing apoptosis and rejuvenating tissues. In aged mice this approach improved kidney function, fur density, and mobility—demonstrating enhanced health-span even when lifespan remained unchanged.

Eliminating senescent cells reduces chronic inflammation and reallocates resources toward healthy progenitor and stem cells—akin to pruning a tree to encourage vigorous growth.

FOXO proteins integrate insulin/IGF-1 signaling with oxidative stress responses and autophagy. Dysregulated FOXO activity drives fasting hyperglycemia, hyperlipidemia, and diabetes complications. FOXO4-DRI offers a probe to explore downstream insulin pathways and proteasome/autophagy modulation in metabolic disease.

Age-related decline in cardiac proteasome activity permits oxidized proteins to accumulate. Modulating FOXO4 signaling may restore proteasome function and protect myocardium. Similar proteostasis deficits are observed in Parkinson’s, Alzheimer’s, Huntington’s, and ALS, spurring research into whether FOXO4-DRI can slow degenerative progression.

FOXO4-DRI is a senolytic, retro-inverso peptide that removes senescent cells, improves tissue function, and informs studies on aging, metabolism, and degenerative disease. Reported side effects are minimal in murine models; oral bioavailability is poor while subcutaneous delivery is reliable. Animal dosing does not extrapolate to humans. FOXO4-DRI is supplied strictly for in-vitro and licensed laboratory research.

PubMed

Article Author :

The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from https://case.edu/medicine/Case Western Reserve University School of Medicine and a B.S. in molecular biology.

Case Western Reserve University School of Medicine

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

The product information featured on this website pertains exclusively to in-vitro studies. In-vitro studies, also known as ‘in glass’ studies, are conducted outside of living organisms. It’s important to emphasize that these products do not constitute medicines or drugs and have not received FDA approval for the prevention, treatment, or cure of any medical conditions, ailments, or diseases. It is crucial to note that the introduction of these products into the bodies of humans or animals is strictly prohibited by law.